The present invention generally relates to a disposable syringe of the prefilled type. More particularly, the present invention relates to a prefilled, disposable syringe assembly wherein medicament, such as BOTOX®, and diluent separately contained in the syringe. When it is desired to mix the components, a plunger is moved in order to cause intermixing of the components.
Generally, a needle injection in accordance with the present invention includes a syringe body along with a needle disposed in fluid communication with the syringe body and a plunger, with a plunger head disposed within said syringe body.
A saline solution is disposed in said syringe body along with a dried medicament, such as BOTOX®, which is disposed on an inside surface of said syringe body in a position enabling movement of the plunger head in said syringe body to cause reconstitution of the medicament in the saline solution and ejection of the reconstituted medicament through the needle.
In one embodiment of the present invention, needle injector generally includes a syringe body and a needle disposed for fluid communication with the syringe body along with a rupturable membrane disposed between the needle and the syringe body and a plunger, including a plunger head. The plunger head, operable by the plunger, is slidably and sealably engaged with an inside surface of the syringe body and initially disposed within the syringe body at position providing a forechamber and an aftchamber within the syringe body.
A saline solution is disposed in the forechamber and the plunger head prevents transfer of the same saline solution from the forechamber into the aftchamber.
A dried medicament, preferably BOTOX®, is disposed on the inside surface of the syringe body within the aftchamber. The dried medicament has a thickness enabling the plunger head to pass thereover during withdrawal of the plunger from the syringe body, thus causing reconstitution of the medicament in the saline solution.
Thereafter, insertion of the plunger into the syringe body causes the reconstituted medicament to be injected through the needle.
More particularly, the syringe body may be provided with an abrasive perimeter for engaging the inside surface of the syringe body to agitate the dried BOTOX® in order to promote introduction into the saline solution and accordingly reconstitution of the BOTOX® in the saline solution.
In another embodiment of the present invention the needle injector generally includes a syringe body having a first end and a second end with a cylinder extending between the first and second ends. The cylinder includes a bypass disposed between the first and second ends.
A needle is provided and coupled to the syringe body first end and is in fluid communication with the syringe body. A dried medicament is disposed in the bypass and a slidable stopper is disposed between the bypass and the syringe body second end.
A plunger is provided including a plunger head with the plunger head slidably and sealably engaging in an inside surface of the syringe body cylinder and initially disposed within the syringe body proximate the syringe body second end.
A saline solution is disposed within the syringe body between the slidable stopper and the plunger head.
The plunger, and plunger head, are movable within the syringe body from proximate the syringe body second end toward the syringe body first end. This movement forces the stopper toward the syringe body front end and the bypass enables flow of the saline solution pass the stopper when the stopper is aligned with the bypass. The flow of saline solution through the bypass causes reconstitution of the dried medicament in the saline solution.
Further forward movement of the plunger head causes engagement with the stopper after all of the saline solution flows through the bypass. Continued movement of the plunger head and stopper causes ejection of the reconstituted medicament through the needle. The dried medicament again is preferably botulinum toxin.
In yet another embodiment of the present invention, the needle injector generally includes a syringe body having a first end and a second end with a cylinder extending between the first and second ends. A slidable piston including a permeable septum is disposed in the cylinder between the first and second ends.
A needle is provided and coupled to the syringe body first end and is in fluid communication with the syringe body, dried medicament is disposed in the cylinder between the syringe body first end and the piston, and a slidable stopper is disposed in the cylinder been the first and second ends.
A plunger is provided including a plunger head with the plunger head slidably and sealably engaging in an inside surface of the syringe body cylinder and initially disposed within the syringe body proximate the syringe body second end.
A saline solution is disposed within the syringe body between the slidable piston and the plunger head. The stopper may be sized in order to provide sealing fractional engagement with the syringe body inside surface or, alternatively, may include wings for releasably engaging an enlarged diameter of the cylinder to prevent premature movement of the stopper and provide sufficient resistance to movement for the enabling saline solution to pass therethrough as hereinafter discussed in greater detail.
The plunger, and plunger head, are movable within the syringe body from proximate the syringe body second end toward the syringe body first end. This movement forces the saline solution through the permeable septum toward the syringe body first end. The flow of saline solution through the septum enables reconstitution of the dried medicament in the saline solution.
Further forward movement of the plunger head causes engagement with the piston after all of the saline solution flows therethrough. Continued movement of the plunger head and piston causes ejection of the reconstituted medicament through the needle. The dried medicament is preferably botulinum toxin.
The present invention may be more clearly understood with reference to the appended drawings of which:
With reference to
A plunger 20 includes a plunger head 22 slidably and sealably engaging an inside surface 24 of the syringe body 12.
As shown in
A dried medicament 36, preferably BOTOX®, in an amount of perhaps 100 microliters is deposited on the inside surface 24.
The dried medicament has a thickness of, for example, about a few mils or less. With the use of a syringe body 12 having a diameter of between about 118 mils and about ½ inch, the plunger head 22 passes over the dried medicament during withdrawal of the plunger 20 from the syringe body 12 as shown in
The plunger head 22 initially prevents transfer of the saline solution 40 from the forechamber 30 into the aftchamber 32.
Withdrawal of the plunger 20 and plunger head 22 exposes the medicament 36 to the saline solution 40, thus enabling reconstitution of the medicament 36 into the saline solution 40. It should be appreciated that a perimeter 46 of the plunger head 22 may include an o-ring or a otherwise roughened surface in order to agitate the medicament 36 upon a passage thereover as is shown in
After reconstitution, as shown in
It should be appreciated that the membrane 16 may be configured for rupture, as the plunger 20 is withdrawn from the syringe body 12, as shown in
With reference to
A needle 124 is coupled to the syringe body front end 114 and is in fluid communication with the syringe body 112. A dried medicament 130, such as botulinum toxin, is disposed in the bypass 122.
A slidable stopper 134 is disposed between the bypass 122 and the syringe body second end 116 and a plunger 136 including a plunger head 140 is provided with the plunger head 140 slidably and sealably engaging an inside surface 142 of the syringe body 112. The plunger head 140 is initially disposed proximate the syringe body second end 116, as shown in
In operation, as shown in
Continued movement of the plunger head 140 causes engagement with the stopper 134 after passage of all of the saline solution through the bypass 132. The saline solution 146 with reconstituted medicament 134 is then ejected through the needle 124 by the stopper 134, plunger head 140 in a conventional manner.
With reference now to
A needle 224 is coupled to the syringe body first end 214 and is in fluid communication with the syringe body 212. A dried medicament 230, such as botulinum toxin, is disposed in the cylinder 220.
A slidable piston 234 is disposed between the syringe body first and second ends 214, 216 and a plunger 236 including a plunger head 240 is provided with the plunger head 240 slidably and sealably engaging an inside surface 242 of the syringe body 212. The plunger head 240 is initially disposed proximate the syringe body second end 216, as shown in
As shown, the piston includes a permeable septum 248, which may be a membrane or rupturable portions of the piston 234, or valves for enabling passage of the saline solution 246 through the piston upon pressure executed by the plunger head 240. The piston may be sized and formed of a material providing sufficient engaging friction with the inner surface 242 so that the stopper remains in portion during passing of saline solution therethrough.
Alternatively, wings 250, or the like, shown in dashed line, may be provided on the stopper 234 for engaging the inner surface 242. Also, a ring 252 of enlarged cylinder 220 diameter may be provided for engaging the wings to maintain the stopper 234 in an initial position as the saline solution passes therethrough, the stopper 234 eventually being moved by engagement with the plunger head 240.
In operation, as shown in
Continued movement of the plunger head 240 causes engagement with the piston 234 after passage of all of the saline solution through the septum 248. The saline solution 246 with reconstituted medicament 234 is then ejected through the needle 224 by the piston 234, plunger head 240 in a conventional manner.
Although there has been hereinabove described specific embodiments of BOTOX® needle injectors in accordance with the present invention for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. That is, the present invention may suitably comprise, consist of, or consist essentially of the recited elements. Further, the invention illustratively disclosed herein suitably may be practiced in the absence of any element which is not specifically disclosed herein. Accordingly, any and all modifications, variations or equivalent arrangements which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.
This is a national stage application under 35 U.S.C. § 371 of PCT application PCT/US 2005/019410, filed May 31, 2005, which claims the benefit of Provisional application No. 60/589,946, filed on Jul. 21, 2004; Provisional application No. 60/589,655, filed on Jul. 21, 2004; and Provisional application No. 60/591,506, filed on Jul. 27, 2004.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US05/01940 | 1/20/2005 | WO | 4/30/2007 |
Number | Date | Country | |
---|---|---|---|
60589946 | Jul 2004 | US | |
60589655 | Jul 2004 | US | |
60591506 | Jul 2004 | US | |
60539922 | Jan 2004 | US |